financetom
Business
financetom
/
Business
/
Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial
Dec 16, 2024 1:37 PM

04:22 PM EST, 12/16/2024 (MT Newswires) -- Merus (MRUS) said Monday the first person has been dosed in its phase 2 trial assessing petosemtamab in heavily pretreated metastatic colorectal cancer.

"In preclinical CRC models, petosemtamab consistently demonstrates superior activity compared to cetuximab, a mainstay therapy in mCRC," said Merus Chief Technology Officer John de Kruif.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US House panel subpoenas tech giants over foreign communications
US House panel subpoenas tech giants over foreign communications
Feb 27, 2025
WASHINGTON, Feb 27 (Reuters) - The U.S. House Judiciary Committee has subpoenaed eight major technology companies, including Alphabet, Meta, Apple ( AAPL ) and X Corp, seeking details about their communications with other countries regarding compliance with laws impacting speech, it said on Thursday. House Judiciary Committee Chairman Jim Jordan, a Republican, sent the subpoenas on Wednesday and also included...
Kymera Therapeutics Q4 Net Loss Widens, Collaboration Revenue Falls
Kymera Therapeutics Q4 Net Loss Widens, Collaboration Revenue Falls
Feb 27, 2025
08:53 AM EST, 02/27/2025 (MT Newswires) -- Kymera Therapeutics ( KYMR ) reported a Q4 net loss Thursday of $0.88 per diluted share, wider than the loss of $0.25 a year earlier. Analysts polled by FactSet expected a loss of $0.86. Collaboration revenue for the quarter ended Dec. 31 was $7.4 million, down from $47.9 million a year earlier. Analysts...
NCR Voyix Posts Q4 Adjusted Earnings Above Analysts Estimates; Revenue Falls; 2025 Guidance Set
NCR Voyix Posts Q4 Adjusted Earnings Above Analysts Estimates; Revenue Falls; 2025 Guidance Set
Feb 27, 2025
09:35 AM EST, 02/27/2025 (MT Newswires) -- NCR Voyix ( VYX ) reported Q4 non-GAAP earnings Thursday of $0.22 per diluted share. The year-earlier figure was not provided. Analysts polled by FactSet expected $0.11 per share. Revenue for the quarter ended Dec. 31 was $682 million, down from $796 million a year earlier. No comparable revenue estimates were available. NCR...
Dyne Therapeutics Q4 Net Loss Narrows; Shares Rise
Dyne Therapeutics Q4 Net Loss Narrows; Shares Rise
Feb 27, 2025
09:41 AM EST, 02/27/2025 (MT Newswires) -- Dyne Therapeutics ( DYN ) shares were up 1.7% in early trading Thursday after the company reported a Q4 net loss of $0.88 per diluted share, compared with a $1.09 loss a year earlier. Analysts polled by FactSet expected a $0.94 loss. The company did not report revenue for the quarter ended Dec....
Copyright 2023-2026 - www.financetom.com All Rights Reserved